Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy in transgender women can affect hair growth and acne, and there are specific skin issues related to gender-affirming surgery, but more research is needed on their dermatological health.

LGBT individuals have unique skin health needs, including higher STD risks and side effects from gender-affirming treatments, requiring dermatologists to offer knowledgeable and culturally competent care.

Hormone therapy and surgeries for transgender individuals affect their skin and hair, requiring specific dermatologic treatments and respectful care.

Dermatologists are essential in helping transgender and gender diverse patients with skin and hair issues related to gender affirmation and hormone therapy.

Laser hair removal before genital surgery can prevent complications and improve patient satisfaction.

Hormone therapy affects hair growth in transgender individuals, with testosterone potentially causing hair loss in trans men and estrogen reducing facial/body hair in trans women; treatment options vary.

Intravaginal testosterone cream improves sexual satisfaction and reduces vaginal discomfort in postmenopausal women on breast cancer treatment without affecting hormone levels.

The Men's Training Cup Keep Training masturbation aid may help delay ejaculation and improve erectile function.

Imiquimod used intravaginally for cervical issues can cause temporary hair loss, especially if severe side effects occur.

DHEA may help with sexual function when used intravaginally by menopausal women but is similar to hormone therapy in other aspects and might cause more side effects like acne and hair loss.

Two women experienced temporary hair loss and other side effects from imiquimod treatment for cervical issues, which stopped after ending the treatment.

A woman had both Graham Little-Piccardi-Lassueur syndrome, causing hair loss, and complete androgen insensitivity syndrome, making her genetically male but physically female. This suggests androgens don't affect the hair loss condition.

A 1-day or 3-day itraconazole treatment is effective for acute vulvovaginal candidosis, but recurrent cases may need longer treatment.

The document concludes that women should not use 5-alpha-reductase inhibitors due to the risk of birth defects and limited effectiveness.

Melatonin may help with sleep issues, depression, and cancer, but more research is needed.

Toxic Shock Syndrome mainly affects menstruating women, can recur, and is linked to staph bacteria, with rapid treatment being crucial.

Some skin medications are safe during pregnancy and breastfeeding, but others can harm the baby and should be avoided.

Androgens play a role in female sexual function, and testosterone therapy can help women with low sexual desire, but more research is needed on treatments and long-term safety.

Products should be called 'sperm-safe' only after thorough, well-designed tests.

Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.

Premature ovarian insufficiency (POI) can harm women's sexual health, and they may benefit from hormone therapy and counseling.

Nanomaterials in biomedicine can improve treatments but may have risks like toxicity, needing more safety research.

Transgender patients need proper skin care, especially when undergoing hormone treatments, to manage issues like acne and hair loss.

Delayed ejaculation is a complex issue caused by psychological, biological, and lifestyle factors, requiring a holistic treatment approach.

Using micro-needling, low-level laser therapy, and platelet-rich plasma together significantly improves hair growth in people with hair loss.

Using systemic drugs as creams for skin conditions shows promise, but more research is needed to confirm their effectiveness and safety.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Testosterone significantly affects sexual desire in both men and women, but its impact on women is more complex and influenced by psychological factors.

Testosterone therapy can modestly improve sexual function in menopausal women but should be used cautiously and is not recommended for routine measurement in sexual dysfunction or hirsutism.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.